Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology
Kaplan–Meier plots of overall survival in unmatched and matched... | Download Scientific Diagram
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA. JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - ScienceDirect
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer - ScienceDirect
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer | Future Oncology
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - The Lancet
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer | SpringerLink
